GlassScriptPrepare for your visit
Ningxin Wan
Advanced Heart Failure and Transplant Cardiology · Flushing, NY · NPI 1689089484
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$6,527.94
in general payments reported to CMS, 2019-2025 · $4,322 in 2025
The $4,322 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Who reported paying
General payments only, top 6 by amount.
- Chiesi USA, INC. $3,712.50
- Abbott Laboratories $1,411.74
- Abiomed $345.54
- Boehringer Ingelheim Pharmaceuticals, INC. $321.28
- Alnylam Pharmaceuticals INC. $187.45
- Actelion Pharmaceuticals US, INC. $132.11
Drugs and devices associated with these payments
Elfabrio Thoratec Heartmate 3 Lvas Implant Kit Impella Jardiance Cardiomems Amvuttra Uptravi Camzyos Opsumit Thoratec Heartmate 3 Eliquis Furoscix
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Ningxin Wan listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/9626356/ningxin-wan